Trial Profile
PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration; Central serous chorioretinopathy; Polypoidal choroidal vasculopathy
- Focus Pharmacodynamics
- Acronyms PRaCTICAL
- 25 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 25 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.
- 25 Jan 2021 Status changed from not yet recruiting to recruiting.